AURO-LOSARTAN 25.0 MG
LOSARTAN POTASSIUM : 25.0 MG · DIN 02403323 · AURO PHARMA INC
Health Canada status: MARKETED
What is AURO-LOSARTAN?
AURO-LOSARTAN 25.0 MG contains LOSARTAN POTASSIUM : 25.0 MG. It is listed in the Health Canada Drug Product Database under DIN 02403323, held by AURO PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 26-Mar-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AURO-LOSARTAN used for?
Treatment of essential hypertension; hypertension with left ventricular hypertrophy; type 2 diabetic patients with proteinuria and hypertension to delay renal disease progression.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02403323 |
|---|---|
| Brand name | AURO-LOSARTAN |
| Generic / active ingredient | LOSARTAN POTASSIUM : 25.0 MG |
| Manufacturer | AURO PHARMA INC |
| Strength | 25.0 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09CA01 LOSARTAN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-Mar-2013 |
How is it administered?
Hypertension: Usual starting dose 50 mg once daily; range 50-100 mg. Type 2 Diabetes with Proteinuria: Usual starting dose 50 mg once daily, may increase to 100 mg. Can be taken with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (Section 11 header present but content missing), though typically 15-30°C for this class.
How is it supplied?
25 mg: Blister packs (2x14, 10x10), HDPE containers (90, 100, 500, 1000). 50 mg & 100 mg: Blister packs (2x14, 10x10), HDPE containers (30, 100, 500, 1000).
Contraindications
Hypersensitivity to the drug or ingredients. Concomitant use with aliskiren-containing drugs in patients with diabetes or moderate to severe renal impairment (GFR <60 ml/min/1.73m2).
Warnings and precautions
Hypotension (especially in volume-depleted patients), valvular stenosis, dual blockade of RAS, renal function changes in susceptible individuals, hyperkalemia.
Is LOSARTAN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09CA01 LOSARTAN. 27 of 81 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-LOSARTAN | 100.0 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02403358 |
| AURO-LOSARTAN | 50.0 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02403331 |
| COZAAR | 100 MG | TABLET | ORGANON CANADA INC. | MARKETED | DIN 02182882 |
| COZAAR | 25 MG | TABLET | ORGANON CANADA INC. | MARKETED | DIN 02182815 |
| COZAAR | 50 MG | TABLET | ORGANON CANADA INC. | MARKETED | DIN 02182874 |
| JAMP-LOSARTAN | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02398850 |
| JAMP-LOSARTAN | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02398834 |
| JAMP-LOSARTAN | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02398842 |
| LOSARTAN | 100 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02388898 |
| LOSARTAN | 100 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02388812 |
Who else supplies LOSARTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LOSARTAN appears in 4256 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.